{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:12:42Z","timestamp":1786461162204,"version":"build-2736575974"},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>Based on their pharmacological target, two classes of calcitonin\u2010gene\u2010related peptide (CGRP) monoclonal antibodies (mAbs) have been identified: antibodies against the CGRP ligand\u2014galcanezumab, fremanezumab, eptinezumab\u2014and antibodies against the CGRP receptor (CGRP\u2010R), erenumab. The aim of the present study was to compare anti\u2010CGRP versus anti\u2010CGRP\u2010R mAbs in patients with high frequency episodic and chronic migraine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All patients on monthly treatment with anti\u2010CGRP mAbs with an available 6\u00a0months\u2019 follow\u2010up at January 2022 were included. Data on efficacy outcome were collected following one (T1), three (T3) and six (T6) months of treatment, and included monthly headache\/migraine days, the Migraine Disability Assessment Scale (MIDAS) and Headache Impact Test 6 (HIT\u20106) scores, pain intensity, analgesics consumption and response rates (&gt;50% headache days reduction compared to baseline).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In all, 152 patients were enrolled, of whom 68 were in treatment with anti\u2010CGRP mAbs (49 galcanezumab, 19 fremanezumab) and 84 with the anti\u2010CGRP\u2010R (erenumab). MIDAS scores were significantly lower in the anti\u2010CGRP group at T1 and T3 (respectively <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.02 and <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.03) as well as the number of mean migraine days at T3 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). At T3 and T6 outcome measures were comparable, although a significantly higher percentage of super\u2010responders was found in the anti\u2010CGRP group (respectively <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.04 and <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), with a similar overall percentage of responders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The present study on a real\u2010world sample confirms the beneficial effect of both anti\u2010CGRP and anti\u2010CGRP\u2010R mAbs, with a more favorable outcome for anti\u2010CGRP antibodies.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ene.15761","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T14:40:26Z","timestamp":1677681626000},"page":"1764-1773","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["An observational study on monoclonal antibodies against calcitonin\u2010gene\u2010related peptide and its receptor"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4365-8278","authenticated-orcid":false,"given":"Francesca","family":"Schiano\u00a0di\u00a0Cola","sequence":"first","affiliation":[{"name":"Neurology Unit, Department of Clinical and Experimental Sciences Universit\u00e0 degli Studi di Brescia  Brescia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bolchini","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Clinical and Experimental Sciences Universit\u00e0 degli Studi di Brescia  Brescia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Ceccardi","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Clinical and Experimental Sciences Universit\u00e0 degli Studi di Brescia  Brescia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Caratozzolo","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Clinical and Experimental Sciences Universit\u00e0 degli Studi di Brescia  Brescia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Liberini","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Clinical and Experimental Sciences Universit\u00e0 degli Studi di Brescia  Brescia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Rao","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Clinical and Experimental Sciences Universit\u00e0 degli Studi di Brescia  Brescia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Padovani","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Clinical and Experimental Sciences Universit\u00e0 degli Studi di Brescia  Brescia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0807-1"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1212"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010600"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419835459"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14193"},{"issue":"2","key":"e_1_2_12_7_1","first-page":"192","article-title":"Analysis of initial non responders to galcanezumab in patients with episodic or chronic migraine: results from the EVOLVE\u20101, EVOLVE\u20102, and REGAIN randomized, double\u2010blind","volume":"59","author":"Nichols R","year":"2019","journal-title":"placebo\u2010controlled studies Headache"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2260"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15236"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15563"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15197"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01247-1"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006640"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779543"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13951"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01408-w"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/25158163211026646"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.649143"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106893"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/01616412.2021.1940672"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14075"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13432"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010715-103120"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.197"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420983282"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1706656114"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211048765"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.15761","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ene.15761","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.15761","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T05:53:00Z","timestamp":1692510780000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.15761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/ene.15761"],"URL":"https:\/\/doi.org\/10.1111\/ene.15761","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"assertion":[{"value":"2023-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}